药物稳定性 348条(本栏目收费,不能显示细节,电话15274084725)
Dosage Level and Toxicity Considerations 202
Nonstoichiornetric Interactions with Water 204
Parenteral Solid Products 204
10.l. Lyophilized products 204
10.2. Stability of crystalline and amorphous lyophilates 205
10.3. The labeling dilemma of parenteral products 205
States of Matter: Crystallinity and Amorphicity 210
Solubilities of Polymorphs 213
Rates of Conversion in Moist Storage 215
Equilibrium Moisture Content of Solids and Hygroscopicity 215
Critical Moisture Content 219
Equilibrium Moisture Curves for Salt Hydrates 221
Moisture EquilibriumC urves of a Smooth Nature 224
Water Absorption “Isotherms” into Amorphates 226
Moisture Exchange Between. Dosage Form Ingredients 228
Equilibrium Moisture Contents for Macromolecules 231
Adsorption Isotherms of Silica 231
Preformulation’s Place in the Stability Function 238
Timing and Goals of Preformulation 239
Physicochemical Parameters 239
3.1. pK and ionizable substances 240
4.1, Use of salt formation to increase solubility 241
4.2. Nonionizable substances 242